Abstracts tagged "epidemiologic methods and vasculitis"

Abstract Number: 2958 • 2016 ACR/ARHP Annual Meeting
Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden
Christopher Sjöwall¹, Thomas Mandl² and Aladdin Mohammad^3,4, ¹Linköping University, Department of Clinical and Experimental Medicine Rheumatology/AIR, Linköping, Sweden, ²Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, ³Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Addenbrooke’s Hospital, Vasculitis and Lupus Clinic, Cambridge, UK, Cambridge, United Kingdom
Background/Purpose: Since first described by McDuffie et al. in 1973, hypocomplementemic urticarial vasculitis (HUV) syndrome has been recognized as a specific autoimmune disorder involving at…
Abstract Number: 749 • 2013 ACR/ARHP Annual Meeting
High Clinical Remission Rate With Relatively High Incidence Of Serious Infection In Newly-Onset ANCA-Associated Vasculitides In Japan – A Report From The Nationwide Prospective Cohort Study
Masayoshi Harigai¹, Ken-ei Sada², Takao Fujii³, Masahiro Yamamura⁴, Yoshihiro Arimura⁵ and Hirofumi Makino², ¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, ³Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Center for Rheumatology, Okayama Saiseikai Hospital, Okayama, Japan, ⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Clinical characteristics and antineutrophil cytoplasmic antibody (ANCA)-serology of ANCA-associated vasculitis (AAV) patients are substantially different between Western and Asian countries. We investigated effectiveness and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].